Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 125,606

Document Document Title
WO/2017/066488A1
Provided herein are methods and compositions for effective treatment or prevention of pain, which also reduce or eliminate adverse effects associated with an opioid analgesic. In addition, provided herein are methods and compositions for...  
WO/2017/066590A1
This disclosure features combinations of NMDA modulators and atypical antipsychotics. The disclosure provides for example, methods of treating schizophrenia, bipolar disorder, and/or cognitive impairment disorder in a patient in need the...  
WO/2017/066444A1
Methods for treating learning disabilities associated with fetal alcohol syndrome and other neurological disorders by administering SK channel blockers, antagonists, inhibitors or modifiers like tamapin.  
WO/2017/064876A1
Provided is a prophylactic and therapeutic agent for Rett syndrome (RTT). A medicinal composition that comprises ghrelin and a pharmacologically acceptable carrier; and a prophylactic and therapeutic agent for RTT that comprises a therap...  
WO/2017/064098A1
The present invention relates to the use of naltrexone for the manufacture of a medicament for the treatment of somatoform pain disorder or persistent pain disorder. The medication is characterized by significant reduction of the symptoms.  
WO/2017/065314A1
The present invention pertains to a method for producing a royal jelly fraction, the method including eluting royal jelly in water and obtaining a residue, eluting the resulting residue in 50% ethanol and obtaining a residue, then elutin...  
WO/2017/063581A1
Provided is an oral preparation for cardiovascular diseases containing a compound 1, wherein the oral preparation is prepared into a large tablet by means of a dry granulation process, the large tablet comprises the compound 1, a filler,...  
WO/2017/066729A1
Provided are novel methods for the treatment or prophylaxis of pain in a feline in need thereof comprising administering to the feline an effective amount of 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically accep...  
WO/2017/065602A1
The disclosure provides novel methods of treating neuromuscular or neurologic disease, for example, Amyotrophic lateral sclerosis (ALS), through reducing GABAergic and Glycinergic inhibitory neurotransmitter activity overstimulation. Pha...  
WO/2017/066730A1
Provided are novel methods for the treatment or prophylaxis of pain in an equine in need thereof comprising administering to the equine an effective amount of 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acce...  
WO/2017/066204A1
The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-bin...  
WO/2017/060870A1
The present invention relates to new combinations of treatments for abnormal dopamine deficiency disorders, and related conditions, comprising deuterated catecholamine derivatives and catechol-O-methyltransferase (COMT) inhibitors.  
WO/2017/062875A1
Compositions and methods for administration of local anesthetics that are delivered by a single injection and enable repeated on-demand or high influx analgesia over extended periods have been developed. Pharmaceutical compositions inclu...  
WO/2017/062974A1
Provided are methods for treatment and prevention of ischemia- reperfusion injury and chronic intermittent hypoxia related injury through administering a neuroprotective compound. A subject benefiting from the method of the invention may...  
WO/2017/060530A1
The invention relates to compounds of formula (I), particularly for the use thereof as a medicament, especially in the treatment or prevention of neurogenerative disorders. The invention also relates to the methods for producing said com...  
WO/2017/062657A1
Methods and compositions for treating traumatic brain injury. The methods and compositions utilize a multi-functional oxygen reactive polymer (ORP) that includes repeating units that include a reactive oxygen species (ROS) scavenging gro...  
WO/2017/060287A1
The present invention relates to a process for the preparation of an amide from a carboxylic acid chloride and an organic molecule comprising both a primary amine group and a tertiary amine group, wherein the nitrogen atom of the tertiar...  
WO/2017/060510A1
The present invention relates to methods and pharmaceutical compositions for the treatment of Alzheimer's disease. In particular, the present invention relates to a method of treating Alzheimer's disease in a subject in need thereof comp...  
WO/2017/059966A1
The invention relates to pyrazolyl substituted tetrahydropyranylsulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or pro...  
WO/2017/059965A1
The invention relates to pyrazolyl substituted tetrahydropyranylsulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or pro...  
WO/2017/059554A1
The present invention relates to a method and use of the AAV-XBP1S/GFP virus in the prevention and treatment of amyotrophic lateral sclerosis, as presented in the in vivo studies in figure 6/9.  
WO/2017/059485A1
The present invention relates to compositions and methods for protecting and/or promoting repair of the nervous system. In particular, the present invention relates to the use of muramyl dipeptide crosslinked to form a microparticle for ...  
WO/2017/062682A3
The present invention concerns methods for treating multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.  
WO/2017/062568A1
The invention relates to methods of determining if a subject is at risk of developing post-traumatic stress disorder (PTSD).  
WO/2017/062270A1
Methods of diagnosis and methods of treatment and prevention for autism spectrum disorder are provided using decoy antigens to maternal brain-reactive antibodies.  
WO/2017/060290A1
The present invention relates to a crystalline forms of encenicline hydrochloride and a process for their preparation. The invention also concerns a pharmaceutical compositions comprising an effective amount of the crystalline form of en...  
WO/2017/060406A1
The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3Kβ in...  
WO/2017/062238A1
The present invention provides methods and compositions for diagnosing and treating intellectual disability (ID). The invention also provides methods and compositions for developing and using in-vitro and in vivo models for diagnosis and...  
WO/2017/059486A1
The present invention relates to compositions and methods for the treatment of epilepsy. In particular, the present invention relates to the use of muramyl dipeptide crosslinked to form a microparticle for reducing the frequency and/or s...  
WO/2017/060202A1
The present invention relates to compounds of formula I; wherein R1' is CH3 R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1 and R1 may form together a l,l-dioxo-tetrahydro-thiophen-3-yl ring; R is hydrogen, methyl, ethyl, is...  
WO/2017/060750A1
The invention relates to the use of a composition from a plant extract of Withania somnifera, to treat or limit development of pathologies of the myelin, including multiple sclerosis disease.  
WO/2017/062682A2
The present invention concerns methods for treating multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.  
WO/2017/061125A1
The present invention provides a therapeutic agent or prophylactic agent for psoriasis, multiple sclerosis, and reduction of side effects caused by TLR-base/IMQ/immunostimulatory adjuvants. It was found that CARD14 is linked to psoriasis...  
WO/2017/062924A1
Dosing regimens and methods are disclosed for upregulating protein kinase C (PKC) while reducing subsequent downregulation, comprising administering a PKC activator once a week for three consecutive weeks followed by cessation of adminis...  
WO/2017/061534A1
The present invention provides a compound which has an effect of inhibiting amyloid β production, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production, s...  
WO/2017/055481A1
Disclosed are compositions containing an extract of Curcuma spp, optionally as curcumin in the form of a complex with phospholipids, and a lipophilic extract of Zingiber officinale, for use in the treatment of osteoarthritis.  
WO/2017/057562A1
The present invention provides a therapeutic agent and/or a prophylactic agent and the like for a peripheral nerve disorder or a spinal injury having zonisamide or an alkali metal salt thereof as an active ingredient.  
WO/2017/058689A1
The invention is directed to novel anhydrous crystalline butenedioate salt form 1 of Compound I, which is a modulator of muscarinic M1 receptors. The novel crystalline forms of compound I are useful in the treatment or prevention of Alzh...  
WO/2017/057717A1
Provided is a heteroaromatic derivative which is represented by general formula (I), has an OX receptor antagonistic activity and is useful as a therapeutic or prophylactic drug for diseases mediated by an OX receptor, or a pharmaceutica...  
WO/2017/055592A1
The invention provides compound that inhibit or modulate the activity of p70S6 kinase, the compounds being of the formula (I) or a salt, tautomer or N-oxide thereof; wherein: one of Y and Z is R3 and the other is Ar2; Q1 is an optionally...  
WO/2017/055632A1
Trilobine and its natural triple-bridged bisbenzylisoquinoline alkaloidal analogues as DNMT inhibitors for use as a drug for the treatment of cancer and neurological diseases and for cell reprogramming, in particular to prime for chemoth...  
WO/2017/055337A1
The present invention relates to an aqueous composition comprising apomorphine or a pharmaceutically acceptable salt or solvate thereof, reduced glutathione (GSH) or a pharmaceutically acceptable salt thereof, and ascorbic acid or a phar...  
WO/2017/059113A1
The present disclosure provides methods and compositions for the treatment, identification, diagnosis, and prognosis of dystonia, or dystonia related disorders.  
WO/2017/059118A1
The present disclosure provides methods and compositions for the treatment, identification, diagnosis, and prognosis of dystonia, or dystonia related disorders.  
WO/2017/056338A1
The present invention provides a method for producing a compound represented by formula (I). Thereby provided is a 4-heteroaryl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl) -1H-pyrazole-5-carboxylic acid amide derivative.  
WO/2017/054640A1
The present invention provides a use of tetrahydropalmatine in preparing an anti-cisplatin toxicity medicament, the toxicity comprising renal toxicity, ototoxicity, and neurotoxicity.  
WO/2017/055533A1
(Formula I) Compounds of formula (I) usefull for the treatment of cancer, neurodegenerative disorders and metabolic disorders.  
WO/2017/059106A1
The disclosure provides methods for treating psychiatric diseases, such as schizophrenia, in patients with certain gene polymorphisms using antipsychotic drugs, such as risperidone and paliperidone.  
WO/2017/059385A1
Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium chan...  
WO/2017/058691A1
This invention provides novel processes for the preparation of compounds such as 3-[(1S,2S)-2-hydroxycyclohexyl]-6-[(6-methylpyridin-3-yl)met hyl]benzo[h]-quinazolin-4(3H)-one, salts and derivatives thereof. The compounds synthesized by ...  

Matches 451 - 500 out of 125,606